The current price of 128940.KS is ₩465,000 — it has increased by 9.80% since the previous close. Data as of Nov 5, 2026.
128940.KS is up 13.41% over the past week, down 11.09% over the past month and up 1.31% over the past year. The price is below its 200-day moving average of ₩467,030.
Of the 11 analysts covering Hanmi Pharm. Co., Ltd., 6 rate it a strong buy and 5 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Hanmi Pharm. Co., Ltd. has a market capitalization of ₩5.9T. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Hanmi Pharm. Co., Ltd. posted earnings of ₩954.96 per share against an estimate of ₩3,207.00, missing expectations by 70.22%. Upcoming reports are listed in the earnings calendar.
Hanmi Pharm. Co., Ltd. reported revenue of ₩377.4B in its most recent quarter, which has increased by 4.17% compared with the same quarter a year earlier. Analysts had expected ₩413.17B.
Yes. Hanmi Pharm. Co., Ltd. pays dividends annually. The latest payment of ₩2,000.00 per share has a payment date of Apr 17, 2026, which corresponds to a dividend yield of 0.43%.
In the latest trading session 128940.KS moved between ₩440,000 and ₩478,000, a range of 8.17% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Hanmi Pharm. Co., Ltd. shows a strong buy rating today and a buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Hanmi Pharm. Co., Ltd. is buy. Technical ratings are indicators, not investment advice.
Over the past 52 weeks 128940.KS has traded between ₩302,000 and ₩647,000. The current price is 28.13% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.